Organisation paid for research Program year 2025 Source: CMS Open Payments

Infinity Medical Research

Neither a doctor nor a teaching hospital

Research payments

$352,032

199 payments

Through program year 2025, Infinity Medical Research is reported as receiving $352,032 in research payments, across 199 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $25,911 81
2024 Research $54,548 32
2023 Research $223,946 73
2022 Research $27,010 11
2021 Research $20,616 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. Daiichi Sankyo Inc. $193,591 85 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $81,773 23 payments
  3. Boehringer Ingelheim International GmbH $40,574 82 payments
  4. Eli Lilly and Company $36,094 9 payments
Studies the money was for Research payments · program years 2021–2025
  1. Ds1211-A-U201 $193,591 85 payments
  2. PDE4 Phase III trial in IPF patients $47,278 24 payments
  3. PDE4 Phase III trial in PF ILD $37,038 7 payments
  4. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $32,824 6 payments
  5. PDE4 Phase III trial in PF-ILD $16,447 30 payments
  6. A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) $12,218 8 payments
  7. An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) $7,065 35 payments
  8. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $2,879 1 payment
  9. A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) $2,301 1 payment
  10. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $372 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record